From the Journals

Treating young adults with high LDL may be cost-effective


 

Time to relax the age 40 threshold

The U.S. Preventive Services Task Force and the American College of Cardiology/American Heart Association should emphasize lifetime risk of elevated cholesterol, Paul A. Heidenreich, MD, MS, Stanford University School of Medicine, California, and colleagues write in an accompanying editorial.

“In addition to calculating 10-year risk, we should calculate years of life lost (or QALYs lost) from unhealthy LDL-C levels, and both lifestyle and pharmacologic treatment should be considered to treat high LDL-C in adults regardless of age. We also need to communicate that the mantra ‘lower is better’ applies not only to a single measurement but to lifetime exposure to LDL-C,” the editorialists write.

“I think treatment should be earlier than age 40,” Dr. Heidenreich said in an interview.

“Part of the reason that 40 was chosen as a threshold was because everyone looked at 10-year, or even 20-year risk, and thought there was no reason to worry until you get older. It’s interesting that we never accepted that with high blood pressure. But more and more, we are learning that it is a lifelong process,” he said.

“Statins are getting less and less expensive, and their safety is more and more established with every decade that goes by. I definitely agree with this paper that it would actually make sense to be starting much earlier for those with elevated CVD risk from their high cholesterol.”

The study was supported by the U.S. National Heart, Lung, and Blood Institute (NHLBI), the Medical Research Council, Swindon, U.K. Dr. Moran and Dr. Heidenreich have disclosed no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

COVID-19 has brought more complex, longer office visits
MDedge Cardiology
SUGAR trial finds superior stent for those with diabetes and CAD
MDedge Cardiology
FFR-guided PCI falls short vs. surgery in multivessel disease: FAME 3
MDedge Cardiology
How applicable is ISCHEMIA trial to U.S. clinical practice?
MDedge Cardiology
More than half of people living with HIV have coronary plaque
MDedge Cardiology
FAVOR III China: QFR-guided PCI shows advantage over angiography
MDedge Cardiology
Short DAPT course beneficial after PCI in ‘bi-risk’ patients
MDedge Cardiology
Statins’ effects on CVD outweigh risk for diabetes in RA
MDedge Cardiology
At 5 years, iFR found as effective and safe as FFR for guiding PCI intervention
MDedge Cardiology
AHA 2021 puts scientific dialogue, health equity center stage
MDedge Cardiology